Government advisers Wednesday said it’s time to update the recipe for the COVID-19 vaccines Americans will receive in the fall — targeting a version of the ever-evolving coronavirus called JN.1.
While COVID-19 cases currently are low, more surges are inevitable and manufacturers need time to brew shots for fall. Moderna, Pfizer and Novavax all have tested doses updated to match the JN.1 variant that became dominant last winter.
But just a few months later, numerous offshoots of JN.1 already are on the rise, prompting Moderna and Pfizer to also test a slightly different vaccine formula targeting what’s now the most common U.S. subtype, called KP.2.